anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: The suburethral sling procedure has been widely used as the first-line treatment for female stress urinary incontinence (SUI). This study retrospectively compared the long-term surgical outcomes and complications between retropubic and transobturator suburethral sling procedures.
METHODS: From 2010 to 2022, a total of 533 women with SUI underwent retropubic pubovaginal sling (PVS) or transobturator tape (TOT) procedures using a synthetic polypropylene mesh with or without concomitant anterior colporrhaphy. All patients underwent preoperative videourodynamic studies, Valsalva leak point pressure (VLPP), and voiding efficiency (VE). The success rate, postoperative complications, overactive bladder symptoms, transvaginal urethrolysis, and repeat procedures were compared among different surgical procedures.
RESULTS: Among the patients, PVS was performed in 251 (47.1%) patients and with colporrhaphy in 58 (10.9%), TOT in 174 (32.6%) and with colporrhaphy in 50 (9.4%). The success rate was 87.4% in the PVS group and 75.4% in the TOT group, with or without colporrhaphy (p = 0.001). Urethrolysis was performed in 4.7% of the patients, and repeat suburethral sling procedures were performed in 8.3%. The overall success rate was significantly lower in TOT group, either with high or low VLPP, or with high or low VE. The rate of persistent OAB was significantly higher in TOT group regardless of VLPP or VE, whereas patients with VE < 90% at baseline had a significantly higher rate of postoperative dysuria.
CONCLUSION: TOT procedures had an inferior long-term success rate than PVS procedures for female SUI. Additionally, no differences in the success rate were observed between patients with different bladder functions, high or low VLPP, and high or low VE.
Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. 

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. 

No information is available from controlled clinical studies regarding the use of ZORVOLEX in patients with advanced renal disease. The renal effects of ZORVOLEX may hasten the progression of renal dysfunction in patients with preexisting renal disease. 

Correct volume status in dehydrated or hypovolemic patients prior to initiating ZORVOLEX. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of ZORVOLEX [see Drug Interactions (7)]. Avoid the use of ZORVOLEX in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If ZORVOLEX is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
PURPOSE: To provide a process for producing the attenuated vaccine for varicella zoster viruses(VZV) accompanied by an increase in the yield of the VZV. CONSTITUTION: The VZV infected sensitive cells selected from the human diploid cells are cultured under a sufficiently high nutrition condition until confluent monolayer cultured matter is obtd. These VZV infected cells are infected at the multiplicity of infection as high as possible for practicability and the VZV infected and cultured matter is maintained at the high nutrition state for about 22 to 96 hours. The cultured matter in which the infectious VZV products are maximized is collected. According to this method, the cell density of about 500,000 cells/cm<2> is stationarily obtd. by using a customarily used culture vessel.
OBJECTIVE: Atherosclerosis (AS) is a chronic inflammatory disease of the arterial wall, in which Human Vascular Smooth Muscle Cells (HVSMCs) are involved. Nevertheless, the functions and mechanisms of circRNAs in oxidized Low-Density Lipoprotein (ox-LDL)-induced vascular smooth muscle cells remain unclear.
METHODS: Circ-ABCA1 expression was measured in the models of AS. Then, in the vitro model, oligonucleotide transfection was performed, followed by an analysis of VSMC proliferation, migration, inflammation, and phenotypic switch. Also, in the in vivo model, mice were injected with shRNA lentivirus, followed by histological examination of aortic tissues. Finally, the interaction of circ-ABCA1, miR-885-5p, and ROCK2 was identified.
RESULTS: Circ-ABCA1, was confirmed to be overexpressed in ox-LDL-induced VSMCs and mouse models of AS. Functionally, silencing circ-ABCA1 via oligonucleotide transfection suppressed VSMC proliferation, migration, inflammation, and phenotypic switch in vitro and prevented AS development in mice in vivo. Mechanistically, circ-ABCA1 absorbed miR-885-5p, which targeted ROCK2.
CONCLUSION: Taken together, the data from this study suggest that circ-ABCA1 mediates cellular inflammation and phenotype switching through the miR-885-5p/ROCK2 axis in ox-LDL-induced VSMCs, and the circ-ABCA1/miR-885-5p/ROCK2 axis is a new potential biomarker for the treatment of AS.
The goal of the current study is to assess the acceptability and feasibility of an acceptance-based group to improve diabetes self-management among individuals with Type 1 Diabetes. Interested individuals will participate in a weekly acceptance-based therapy group focusing on improving diabetes management (e.g., adherence to dietary recommendations, appropriate insulin dosing) for a total of 8 weeks. Participants will also be asked to complete questionnaires both pre and post treatment. Questionnaires will assess diabetes management and acceptability of the group (post treatment only). Regular medical monitoring is required for participation in the current study. Participants will be asked to provide consent to contact their current medical provider in order to confirm that the participant's is receiving regular medical monitoring for diabetes care and that providers are aware of their patient's participation in group.
An elastic laminate web is disclosed. The elastic laminate web can be non-apertured or apertured, and comprises a first web, and a second web joined to the first web in a face to face relationship at a plurality of discrete bond sites having an aspect ratio of at least 2. The first and second webs form an interior region therebetween. An elastic material is disposed between the first and second webs. The elastic material is apertured in regions coincident the bond sites, such that the first and second webs are joined through the apertures. The laminate so produced can be stretched in a predetermined direction, such as by incremental stretching, to produce an apertured elastic laminate.
This study will proceed in three phases. In phase 1, the investigators conduct qualitative interviews and focus groups with key informants including military-connected mothers (MCM) to guide adaptation of PSTAIR in Phase 2. The investigators anticipate the outcome of Phase 2 will be a 10-15 session intervention (PSTAIR-M), involving a compact version of PSTAIR in Module 1 and tailored options for Module 2, focusing on mental health (Module 2a) and parental functioning (Module 2b), implemented based on response to Module 1. Phase 3 is a two-arm randomized controlled trial (RCT): PSTAIR (10-15 sessions) vs. treatment as usual (TAU). Eligible cases are randomized to PSTAIR and TAU in a 1:1 ratio. Participants will be trauma-exposed MCM who screen positive for PSTD with/without comorbid depression and one identified child (ages 2-10). Assessments will occur at 3 timepoints. Pre- and post-treatment will include self-report and clinician-administered instruments and dyadic parenting observations. Midpoint assessment (after session 10 to assess change after PSTAIR Module 1) will include only self-report and dyadic observation.
PROBLEM TO BE SOLVED: To obtain an ultraviolet absorber reduced in the tendency toward agglomeration and having improved transparency, dispersibility, and the effect of intercepting ultraviolet rays in region A by coating the surface of a flaky substrate with zinc oxide ultramicroparticles. SOLUTION: At least 0.005 mol, per mol of the zinc salt, of a complexing agent is added to an aqueous suspension containing 100 pts.wt. flaky substrate having a mean particle diameter of 0.5-10.0 μm, and the resulting mixture is heated to 60 deg.C or above. A zinc salt solution and an alkali carbonate are added to the aqueous suspension at a pH of 8 or above, and an alkaline solution is added to adjust the mixture to a pH of 8 or above and to coat the surface of the flaky substrate with the basic zinc carbonate ultramicroparticles. The coated microparticles are then filtered, washed, and fired at 300-900 deg.C, desirably, 500-900 deg.C to coat the surface of 100 pts.wt. flaky substrate with 30-250 pts.wt., desirably, 50-150 pts.wt., more desirably, 70-130 pts.wt. zinc oxide microparticles having a mean particle diameter of 100 nm or lower.
PURPOSE:To enable efficient production of the subject enzymatically decomposed soybean protein by acting a protease (PTE) on a soybean protein (-containing material). CONSTITUTION:Soybeans are defatted, subjected to water extraction and subsequently subjected to isoelectric point precipitation to obtain an isolated soybean protein (A) from which whey is removed. To the component (A), an aqueous solvent such as water, a buffer solution or a low-concentration alcohol-containing aqueous solution is then added in an amount of 5-20 times (W/W) the amount of (A) and the resultant mixture is sterilized at about 121 deg.C/1atm for 5-20min. pH is then adjusted to a desired value to obtain a substrate solution (B). PTE such as an alkali protease is subsequently added to the solution (B) and the resultant mixture is reacted at 25-40 deg.C for 15-30hr to obtain a reaction product (C). The component (C) is then heat treated at about 100 deg.C for deactivation of PTE and, after adjustment of its pH to a value in the vicinity of neutral pH, decomposition residues are removed by centrifugal separation, etc., thus obtaining the objective enzymatically decomposed soybean protein capable of activation of macrophage.
The radionuclide Tin, Sn-121 in a carrier hydroxide aggregate is disclosed for the treatment of arthritis and, in particular, rheumatoid arthritis of the hands, the interphalangeal joints of the fingers and the metacarpal joints of the hand. The radioactive compound disclosed preferably has a particle size of <90 microns. The beta energy emission associated with Tin, Sn-121 has an energy of 0.38 meV. There are no gamma photons emited during the decay of Tin, Sn-121 to stable Antimony Sb-121. The half life of Tin, Sn-121 is 27.06 hours. The method of preparation of the compound is disclosed along with the method of administration to the patient in need thereof.
Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10 x 10<7> unitllmg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.Lymphotoxin (I) absolutely free from homologous proteins that are unidentified or present in unknown amounts is new. Unglycosylated (I) is new. Variant (I) in which an amino acid residue in the (I) sequence has been deleted or substd. by another residue, or in which another residue has been inserted, is new. Provided that (I) having a sequence with an amino terminal at Leu(+)1 or His(+)23 is excluded. Nucleic acid encoding (I) and selected from (a)-(c) is new. (a) DNA encoding (I) free from DNA encoding other proteins of the organism from which the DNA originated (b) DNA encoding (I) free from untranslated intervening sequences and (c) nucleic acid capable of hybridising to nucleic acid encoding (I), provided that the acid does not have the nucleotide sequence of natural DNA or RNA encoding (I).
The purpose of this prospective/retrospective cohort study is to evaluate the effectiveness of each individual participating mobile health clinic in improving their community's health and access to care, and to compare each clinic's performance and reach within their respective communities. This Institutional Review Board (IRB)-exempt study is a descriptive review of de-identified evaluation, clinical, and operations data, including staff and patient surveys, patient metrics, and clinic operations metrics. The investigators anticipate that additional mobile clinic programs will submit de-identified data from evaluations done under local IRB exemption. The study will utilize data already collected or to be collected by each mobile health clinic as a part of its clinical and operational activities. Each mobile health clinic will decide which indicators from the evaluation instrument it will use for its own evaluation, and which will be reported to the shared database, depending on the specific services provided and population served. Data will be tracked on a per-patient-visit level or per-operational day, whichever is more relevant to the variable at hand. Data will be sourced from each mobile health clinic's current evaluation sources, including patient intake records (for demographic information, clinic visit dates, clinic procedures done), time and budget tracking software (for hours/patient and cost/patient spent), patient questionnaires (for patient satisfaction and attitudes about their mobile health clinic visit), patient post-visit follow-up questionnaires (for simple referral or prescription follow-up), and clinic operational records (for distance traveled).
Patients receive CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
CTA of the abdomen OR or CTA of the chest and abdomen or CTA of the abdomen and pelvis or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
The study implemented a double-blind, randomized, controlled trial design. Participants were tested three times over 7 days. After study enrollment, the participants were randomly assigned to one of three groups: MIActive (receiving active tDCS stimulation and participating in MI protocol), MISham (receiving sham tDCS stimulation and participating in MI protocol), and Control (receiving no stimulation and participating in an unrelated video-watching task) by a research member not associated with data collection. Allocation ratio was 1:1:1 and a block randomization approach was employed to maintain an equal distribution of participants across the three groups throughout the study. Study participants and assessors were blinded to assignment of active or sham tDCS. The independent variables were time (pre, post, and retention trials) and group (MIActive, MISham and Control), and the dependent variables were time to completion of a complex obstacle course and the amount of change in oxygenated hemoglobin (ΔO2Hb) during performance of that task.
This is a 52 week, single masked, 1:1:1, randomized, phase IV, multicenter injection controlled clinical study with a 24 week treatment phase followed by a 24 week follow up phase. Subjects will be randomly assigned to Ozurdex every 16 weeks, Ranibizumab monthly, or combination Ozurdex every 16 weeks with Ranibizumab. Patients assigned to IV Ozurdex arm will receive a total of 2 intravitreal Ozurdex injections (in combination with monthly Ranibizumab sham) administered at 16 week intervals beginning on Day 1 and ending at Week 16. Patients assigned to IV Ranibizumab arm will receive injections administered at monthly intervals (in combination with Ozurdex sham beginning on Day 1 and Week 16). Patients assigned to IV Ozurdex with IV Ranibizumab will receive a total of 2 intravitreal Ozurdex injections administered at Week 16 intervals beginning on Day 1 and ending at Week 16 with an initial IV Ranibizumab injection administered on Day 1, then treated with Ranibizumab according to reinjection parameters assessed monthly through Week 20 (in combination with Ranibizumab sham if Ranibizumab reinjection parameters are not met). Treatment at end of study treatment phase Week 24 will be standard of care for all arms at the Investigator's discretion.
Lipoprotein (a) is a complex lipid molecule that has sparked immense interest in recent years, after studies demonstrated its significant association with several cardiovascular conditions. Lp(a) promotes cardiovascular disease through its combined proatherogenic, pro-inflammatory, and prothrombotic effects. While the measurement of Lp(a) has become widely available, effective methods to reduce its concentration are currently limited. However, emerging data from ongoing clinical trials involving antisense oligonucleotides have indicated promising outcomes in effectively reducing Lp(a) concentrations. This may serve as a potential therapeutic target in the management and prevention of myocardial infarction, calcific aortic stenosis, and cerebrovascular accidents. In contrast, the role of Lp(a) in atrial fibrillation, in-stent restenosis, cardiac allograft vasculopathy, and bioprosthetic aortic valve degeneration remains unclear. This review article aims to thoroughly review the existing literature and provide an updated overview of the evidence surrounding the association of Lp(a) and these cardiovascular diseases. We seek to highlight controversies in the existing literature and offer directions for future investigations to better understand Lp(a)'s precise role in these conditions, while providing a summary of its unique molecular characteristics.
The invention relates to the field of molecular immunology, and in particular provides a polypeptide composition of novel coronavirus omnikom series variant strains and application thereof. The polypeptide composition of the novel coronavirus amikau series variant strain consists of one or more of the following 10 polypeptides, and the amino acid sequences of the polypeptide composition are SEQ ID NO: 1. SEQ ID NO: 2. SEQ ID NO: 3. SEQ ID NO: 4. SEQ ID NO: 5. SEQ ID NO: 6. SEQ ID NO: 7. SEQ ID NO: 8. SEQ ID NO: 9. SEQ ID NO:10, the invention also provides a preparation method and application of the polypeptide composition. The polypeptide composition can form disulfide bonds, accords with the natural structure of viruses, increases immunogenicity, and is easier to artificially synthesize, process and store; the polypeptide of the invention is only synthesized chemically, is not coupled with carrier protein, and can generate higher effective neutralization titer in mice.
It is an object of the present invention to provide preparations for the treatment or prophylaxis of AIDS and systemic lupus erythematosus and related disorders. The invention is based on the discovery of the process triggered in the immune system by HIV which leads to AIDS. HIV has a specific mechanism to activate the immune system to allow it to replicate and this same immune activation leads to an autoimmune process which eventually leads to AIDS. The preparation for treatment comprises novel synthesized peptides whose amino acid sequences are derived from a human protein called ezrin and are based on the following sequence: NH2ThrGluLysLysArgArgGluThrValGluArgGluLysGluCOOH SEQ ID. No. 2. The mechanism of action of these peptides is that they switch off specific retrovirally induced immune responses by immunological tolerance.
This study is a double-blind, placebo-control randomized clinical trial examining the efficacy of Speed of Processing Training (SPT) for improving processing speed (PS) deficits in persons with Multiple Sclerosis (MS). Slowed PS is one of the most common deficits in individuals with MS and such deficits have been shown to exert significant negative impact on multiple aspects of everyday life, including occupational and social functioning. Despite these findings, few studies have attempted to remediate PS deficits in order to improve the everyday functioning of individuals with MS. This study is designed to (1) apply a treatment protocol for PS impairments well-validated in an aging population to individuals with MS with objectively observable deficits in PS and document its efficacy on standard neuropsychological outcome measures. In addition, the investigators will (2) assess the effectiveness of the intervention utilizing global measures of everyday life, including an objective measure (the Timed Activities of Daily Living; TIADL), as well as additional questionnaires to be completed by both the participant and a significant other. This study is also designed to (3) examine the influence of degree of PS impairment on treatment efficacy using neuropsychological tests, (4) evaluate the long-term effects of the treatment protocol and (5) examine the utility of booster sessions to facilitate long-term treatment effects.
The participants qualify for the study will return to the clinic at a later date and will have catheter(s) placed for i.v. administration of 18F- DTBZ for injection. The participants will receive a single i.v. bolus of 18F- DTBZ, followed by brain PET imaging of 10 minutes duration, approximately 80 minutes post-dose injection. Vital signs will be obtained prior to and immediately after the administration of 18F- DTBZ, and at the completion of the imaging session. Adverse events will be continuously monitored during the imaging session. The participants experience any adverse event will not be discharged until the event has resolved or stabilized.
Previous studies have suggested that deafness could lead to deficits in motor skills and other body-related abilities. However, the literature regarding motor skills in deaf adults is scarce and existing studies often included participants with heterogeneous language backgrounds and deafness etiologies, thus making it difficult to delineate the effects of deafness. In this study, we investigated motor learning in deaf native signers and hearing nonsigners. To isolate the effects of deafness and those of acquiring a signed language, we additionally tested a group of hearing native signers. Two well-established paradigms of motor learning were employed, in which participants had to adapt their hand movements to a rotation of the visual feedback (Experiment 1) or to the introduction of a force field (Experiment 2). Proprioceptive estimates were assessed before and after adaptation. Like hearing nonsigners, deaf and hearing signers showed robust adaptation in both motor adaptation paradigms. No significant differences in motor adaptation and memory were observed between deaf signers and hearing nonsigners, as well as between hearing signers and hearing nonsigners. Moreover, no discernible group differences in proprioceptive accuracy were observed. These findings challenge the prevalent notion that deafness leads to deficits in motor skills and other body-related abilities.